Affimed NV (LTS:0HL9)
$ 6.1 -0.37 (-5.72%) Market Cap: 93.50 Mil Enterprise Value: 35.19 Mil PE Ratio: 0 PB Ratio: 1.46 GF Score: 50/100

Q2 2023 Affimed NV Earnings Call Transcript

Aug 10, 2023 / 12:30PM GMT
Release Date Price: $5.48 (-5.24%)
Operator

Good day everyone, and welcome to Affimed Second Quarter 2023 Earnings and Corporate Update Call. As a reminder, today's conference call is being recorded.

I would now like to introduce your host for today's call, Alex Fudukidis, Head of Investor Relations at Affimed. Please go ahead.

Alexander Fudukidis
Affimed N.V. - Head of IR & Director of IR

Thank you, Chris. And thank you all for joining us today for our second quarter 2023 update call. Before we begin, I'd like to remind everyone that we issued the relevant press release and presentation earlier today which can be found on the Investor Relations section of our website.

On the call today, we have the members of our management team, including our Chief Executive Officer, Adi Hoess; Andreas Harstrick, our Chief Medical Officer; Arndt Schottelius, our Chief Scientific Officer; Wolfgang Fischer, our Chief Operating Officer and Denise Mueller, our Chief Business Officer, and Angus Smith, our Chief Financial Officer. The team will be available for Q&A after the prepared remarks.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot